Vector for producing circular RNA

By designing a circular RNA vector containing specific introns and IRES, the problem of insufficient instability and targeting specificity of mRNA vaccines in cells is solved, and the high stability and effective expression of circular RNA is achieved, reducing production Cost and risk of allergic reactions.

CN119013404APending Publication Date: 2024-11-22AGENCY FOR SCI TECH & RES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032883.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-06
Filing Date
2023-04-06
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing mRNA vaccine designs have problems such as low-temperature storage needs, high dose injection, risk of allergic reactions, lack of target specificity and high cost, and linear mRNA is unstable in the cell and is easily degraded by exonucleases.

Method used

Developed vectors for the production of circular RNA, including type 5'I intron fragments, internal ribosome entry sites (IRES), protein coding or non-coding regions and type 3'I intron fragments, and through Precursor RNA was incubated with T4 RNA ligase in the presence of buffer and Mg2+ to generate circular RNA, improving its stability and translation efficiency.

Benefits of technology

The generated circular RNA is highly stable in the cell, reducing the decay rate, reducing stimulation to the cellular immune system, reducing production costs, and improving target specificity and expression efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013404A_ABST
    Figure CN119013404A_ABST
Patent Text Reader

Abstract

The present invention relates generally to the field of molecular biology. In particular, the present invention relates to vectors for the production of circular RNA. Also provided herein are methods of producing circular RNA from precursor RNA transcribed from a vector.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention generally relates to the field of molecular biology. In particular, the present invention relates to a vector for producing circular RNA. Also provided herein is a method for producing circular RNA from a precursor RNA transcribed from a vector. Background Art

[0002] RNA therapy refers to the use of RNA-based molecules to treat or prevent disease. There are a large number of RNA-based molecules that can be used to treat or vaccinate subjects. These include messenger RNA (mRNA) molecules, which can produce therapeutic proteins, or express viral proteins to cause immune responses. Other types of RNA-based molecules include antisense oligonucleotides (ASOs) or RNA interference (RNAi) molecules, which can be used to inhibit the expression of specific genes in patients. RNA molecules are also known to be unstable, and there is a continuous need to improve the stability of RNA molecules for clinical development.

[0003] Current mRNA vaccines utilize modified and capped linear mRNA with a polyA tail. The RNA is then packaged with lipid nanoparticles and delivered to human cells by intramuscular injection. Although highly effective, mRNA vaccine designs have several disadvantages, including the need for low temperatures for transportation and storage, the need for high doses to be injected, the development of allergic reactions due to formulations, lack of target specificity, and high cost. Since most mRNAs in cells are linear, degradation of RNA in mammalian cells occurs primarily through the activity of 5' and 3' exonucleases.

[0004] It would be desirable to overcome or alleviate at least one of the above problems, or at least provide a useful alternative. Summary of the invention

[0005] Disclosed herein is a vector for producing circular RNA, the vector comprising the following elements operably linked to each other and arranged in the following order: a) a 5' type I intron fragment, b) an internal ribosome entry site (IRES), c) a protein coding region or a non-coding region, and d) a 3' type I intron fragment.

[0006] Disclosed herein is a method for producing circular RNA from a precursor RNA transcribed from a vector as defined herein, the method comprising: 2+ The precursor RNA is incubated in the presence of to generate circular RNA from the precursor RNA.

[0007] Disclosed herein are circular RNAs produced by a vector as defined herein.

[0008] Disclosed herein is a method of expressing a protein in a cell, the method comprising transfecting a circular RNA as defined herein into the cell.

[0009] Disclosed herein are nanoparticle compositions comprising circular RNA produced by a vector as defined herein.

[0010] Disclosed herein is a vector for producing circular RNA, the vector comprising the following elements operably linked to each other and arranged in the following order: a) a 5' homologous sequence, b) an internal ribosome entry site (IRES), c) a protein coding region or a non-coding region, and d) a 3' homologous sequence.

[0011] Disclosed herein is a method for producing circular RNA from a precursor RNA transcribed from a vector as defined herein, the method comprising: 2+ The precursor RNA is incubated in the presence of 5% paraformaldehyde and T4 RNA ligase I or II to generate circular RNA from the precursor RNA. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Embodiments of the invention are described below, by way of non-limiting example only, with reference to the accompanying drawings, in which:

[0013] Figure 1 Different ways of circularizing RNA using split intron 1 (left), T4 RNA ligase 1 (middle), T4 RNA ligase 2 (right). Exonic sequences are retained in the circular RNA, but they are only a small fraction (<5%) compared to the 5' or 3' intron fragments.

[0014] Figure 2 Optimization of different features of circular RNA design for efficient translation. On the left, different type 1 introns will be tested as well as different ligases for efficient RNA circularization. In the middle, different internal ribosome entry sites from viral and human sources will be tested for efficient translation. On the right, codon optimization will be performed and the efficiently translated codon-optimized sequence of the spike protein of the SARS-CoV-2 delta variant will be identified.

[0015] Figure 3 Gel electrophoresis showing 0.5 kb insert or 1.5 kb insert RNA circularized with T4 RNA ligase 2 (Rnl2).

[0016] Figure 4 Schematic representation of the secondary structure of a group I intron. Paired regions are numbered P1-P9, and splice sites are indicated by arrows, exons involved in structural interactions near the splice sites are in dashed lines, and the GTP binding site is usually at P7 (G-OH). The replacement intron is generated by cleavage at the loop region of the conserved P6, the 5'-fragment is designated as E1 and the 3'-fragment is E2.

[0017] Figure 5.Self-splicing efficiency of 1 kb constructs of different type 1 introns. Each gel shows the self-splicing efficiency of different type 1 introns under different buffer conditions (AG). The input control (Input) indicates RNA before incubation in folding buffer to promote self-splicing. The green arrow indicates the circular product, while the top band is the linear product.

[0018] Figure 6 The accuracy of self-splicing of different group 1 introns was tested. Top, workflow of reverse transcription and PCR of circular RNA for Sanger sequencing. Bottom, table showing the number of junctions in each category for each group 1 intron.

[0019] Figure 7 Luciferase assay showed that the protein expression from the newly designed group 1 intron and T4 RNA ligase-mediated loop was higher than that from the existing group 1 intron (T4 and An).

[0020] Figure 8 The circular version using CVB3 as the internal ribosome entry site had the highest protein expression levels. A panel of IRES was tested for protein expression levels in Hela cells. A mock (no RNA) was included for control.

[0021] Fig. 9 A. Workflow for circular RNA purification. B. RNase R digestion showing digestion of linear products while retaining circular RNA.

[0022] Fig.10 Workflow for generating circRNA and encapsulating it with peptide nanoparticles.

[0023] Fig.11 The modified An PIE was folded in condition B and mixed with streptavidin C1 beads. After washing and elution, the bound fraction was analyzed by EX gel. These results show that circular RNA prepared from modified An (SEQ NO: 25 and NO: 26) can be purified by streptavidin beads. DETAILED DESCRIPTION

[0024] The present specification teaches vectors for producing circular RNA. Disclosed herein is a vector for producing circular RNA, the vector comprising the following elements operably linked to each other and arranged in the following order: a) a 5' type I intron fragment, b) an internal ribosome entry site (IRES), c) a protein coding region or a non-coding region, and d) a 3' type I intron fragment.

[0025] Without being bound by theory, the inventors have combined expertise in RNA biochemistry and RNA structural biology to develop a robust, cost-effective strategy for producing circular RNA vaccines with increased stability and translatability that is broadly applicable to any pathogen of interest, including RNA viruses and pathogenic bacteria. The inventors have developed a method that enables RNA circularization ( Figure 1 ) and protein translation ( Figure 2 ) strategy. Since these circular RNAs do not have free 5' and 3' ends that can be degraded by nucleases, these endless RNA molecules can be highly stable in cells, so their decay rates span days rather than hours. This characteristic of circular RNA enables it to be used as an expression platform for high and stable production of genes of interest. In addition, although linear mRNA requires modifications including pseudouridylation to escape from the cellular immune system, circular RNA does not require these modifications, reducing the cost of RNA production while maintaining scalability.

[0026] In one embodiment, the vector allows for the production of circular RNA that is translatable and / or biologically active in a cell, such as a eukaryotic cell.

[0027] As used herein, "vector" means a section of DNA that is synthesized (e.g., using PCR) or obtained from a virus, plasmid, or cell of a higher organism into which an exogenous DNA fragment may or has been inserted for cloning and / or expression purposes. In some embodiments, the vector can be stably maintained in an organism. The vector may include, for example, an origin of replication, a selective marker, or a reporter gene such as antibiotic resistance or GFP, and / or a multiple cloning site (MCS). The term includes linear DNA fragments (e.g., PCR products, linearized plasmid fragments), plasmid vectors, viral vectors, cosmids, bacterial artificial chromosomes (BACs), and yeast artificial chromosomes (YACs), etc.

[0028] As used herein, elements of a vector are "operably linked" if they are positioned on the vector so that they can be transcribed to form a precursor RNA, which can then be circularized into a circular RNA using the methods provided herein.

[0029] As used herein, elements of a vector are "operably linked" if they are positioned on the vector so that they can be transcribed to form a precursor RNA, which can then be circularized into a circular RNA using the methods provided herein.

[0030] As used herein, "precursor RNA" refers to a linear RNA molecule generated by in vitro transcription (e.g., from a vector provided herein). This precursor RNA molecule contains the entire circRNA sequence, plus the splicing sequences (e.g., intron fragments or homologous sequences) required for RNA cyclization. These splicing sequences (intron fragments or homologous sequences) are substantially removed from the precursor RNA during cyclization, producing circRNA plus two intron / homologous sequence linear RNA fragments. The precursor RNA can be unmodified, partially modified, or completely modified. In one embodiment, the precursor RNA contains only naturally occurring nucleotides.

[0031] As used herein, the terms "polynucleotide", "polynucleotide sequence", "nucleotide sequence", "nucleic acid" or "nucleic acid sequence" refer to mRNA, RNA, cRNA, cDNA or DNA. The term generally refers to a polymeric form of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide. The term includes single-stranded and double-stranded forms of RNA or DNA.

[0032] As used herein, "RNA" refers to ribonucleic acid that can be naturally or non-naturally present. For example, RNA can include modified and / or non-naturally present components, such as more than one nucleobase, nucleoside, nucleotide, or joint. RNA can include a cap structure, a chain terminating nucleoside, a stem loop, a PolyA sequence, and / or a polyadenylation signal. RNA can have a nucleotide sequence encoding a polypeptide of interest. For example, RNA can be a messenger RNA (mRNA). Translation of an mRNA encoding a specific polypeptide, for example, in vivo translation of an mRNA in a mammalian cell, can produce the encoded polypeptide. RNA can be selected from the non-limiting group consisting of small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), micro RNA (miRNA), Dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA), mRNA, and mixtures thereof.

[0033] As used herein, "modified" means non-natural. For example, RNA can be modified RNA. That is, RNA can include one or more non-naturally occurring nucleobases, nucleosides, nucleotides, or linkers. "Modified" species can also be referred to as "altered" species in this article. A species can be modified or altered chemically, structurally, or functionally. For example, a modified nucleobase species can include one or more non-naturally occurring substitutions.

[0034] "Polypeptide," "peptide," "protein," and "protein molecule" are used interchangeably herein to refer to molecules comprising or consisting of a polymer of amino acid residues, as well as variants and synthetic analogs thereof.

[0035] As used herein, the term "encoding" refers broadly to any process in which information in a polymer macromolecule is used to direct the production of a second molecule that is different from a first molecule. The second molecule may have a chemical structure that is different in nature from that of the first molecule.

[0036] In one embodiment, the 5' and 3' type I intron fragments are from T4 bacteriophage, Cyanobacterium Anabaena, Scytalidium dimidiatum (Sd), Clostridium botulinum (Cb), Scytonema hofmanii (Sh), Geosmithia virida (Gv), Penicillium oblatum (Po) or Barrmaelia oxyacanthae (Bo). In one embodiment, the 5' and 3' type I intron fragments are from the cyanobacteria Anabaena and Scytalidium dimidiatum (Sd).

[0037] In one embodiment, the 5' and 3' type I intron fragments are from Scytalidium dimorphorum (Sd), Clostridium botulinum (Cb), Pseudomonas hessenii (Sh), Joesmithia viridis (Gv), Penicillium oblate (Po), or Xylaria pasteuriana acuminatum (Bo).

[0038] In one embodiment, the 5' and 3' type I intron fragments are from Scytalidium bipunctatum (Sd), Clostridium botulinum (Cb), Pseudoclade helgophytum (Sh), or Penicillium oblate (Po).

[0039] In one embodiment, the 5' and 3' type I intron fragments are from Scytalidium dimorphoside (Sd).

[0040] As used herein, a 3' group I intron fragment is a contiguous sequence having at least 75% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, 100%) sequence identity to the 3' proximal fragment of a native group I intron, and optionally, a contiguous exon sequence of at least 1 nucleotide in length (e.g., at least 5 nucleotides in length, at least 10 nucleotides in length, at least 15 nucleotides in length, at least 20 nucleotides in length, at least 25 nucleotides in length, at least 50 nucleotides in length). In one embodiment, the contiguous exon sequence included is about the length of a native exon.

[0041] In some embodiments, the 5' group I intron fragment is a contiguous sequence having at least 75% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, 100%) sequence identity to the 5' proximal fragment of a native group I intron, and optionally, the adjacent exon sequence is at least 1 nucleotide in length (e.g., at least 5 nucleotides in length, at least 10 nucleotides in length, at least 15 nucleotides in length, at least 20 nucleotides in length, at least 25 nucleotides in length, at least 50 nucleotides in length). In one embodiment, the included adjacent exon sequence is about the length of a native exon.

[0042] In one embodiment, the 5' type I intron fragment comprises or consists of a nucleic acid sequence having at least 70% sequence identity to SEQ ID NO: 1, 3, 5, 7, 9 or 11. The 5' type I intron fragment may comprise or consist of a nucleic acid sequence having at least 70% sequence identity to SEQ ID NO: 5, 7, 9 or 11. The 5' type I intron fragment may comprise or consist of a nucleic acid sequence having at least 70% sequence identity to SEQ ID NO: 5.

[0043] In one embodiment, the 3' type I intron fragment comprises or consists of a nucleic acid sequence having at least 70% sequence identity to SEQ ID NO: 2, 4, 6, 8, 10 or 12. The 3' type I intron fragment may comprise or consist of a nucleic acid sequence having at least 70% sequence identity to SEQ ID NO: 6, 8, 10 or 12. The 3' type I intron fragment may comprise or consist of a nucleic acid sequence having at least 70% sequence identity to SEQ ID NO: 6.

[0044] In another embodiment, the 5' and 3' type I intron fragments are modified 5' and 3' type I intron fragments from the cyanobacterium Anabaena. The 5' type I intron fragment may comprise or consist of a nucleic acid sequence having at least 70% sequence identity to SEQ ID NO: 25. The 3' type I intron fragment may comprise or consist of a nucleic acid sequence having at least 70% sequence identity to SEQ ID NO: 26.

[0045] The term "at least 70% sequence identity" may mean at least 70%, 80%, 90%, 95%, 99% or 100% sequence identity.

[0046] The term "sequence identity" as used herein refers to the degree to which a sequence is identical on a nucleotide-by-nucleotide basis or on an amino acid-by-amino acid basis in a comparison window. Therefore, the "percentage of sequence identity" is calculated in the following manner: two optimally aligned sequences are compared in a comparison window, the number of positions where identical nucleic acid bases (e.g., A, T, C, G, I) or identical amino acid residues (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys, and Met) occur in the two sequences is determined to produce the number of matching positions, the number of matching positions is divided by the total number of positions in the comparison window (i.e., window size), and the result is multiplied by 100 to produce the percentage of sequence identity. For the purposes of the present invention, "sequence identity" will be understood to mean the "percent match" calculated by the DNASIS computer program (Windows version 2.5; available from Hitachi Software engineering Co., Ltd., South San Francisco, California, USA) using standard default values ​​as used in the reference manual of the accompanying software.

[0047] Terms used to describe sequence relationships between two or more polynucleotides or polypeptides include "reference sequence", "comparison window", "sequence identity", "percentage of sequence identity", and "substantial identity". A "reference sequence" is at least 12, but typically 15 to 18, and often at least 25 monomer units in length, including nucleotides and amino acid residues. Because two polynucleotides can each contain (1) a sequence that is similar between the two polynucleotides (i.e., only a portion of the complete polynucleotide sequence), and (2) a sequence that diverges between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing the sequences of the two polynucleotides within a "comparison window" to identify and compare local regions of sequence similarity. A "comparison window" refers to a conceptual segment of at least 6 consecutive positions, typically about 50 to about 100 consecutive positions, more typically about 100 to about 150 consecutive positions, in which a sequence is compared to a reference sequence of the same number of consecutive positions after the two sequences are optimally aligned. Compared with the reference sequence (which does not include additions or deletions) for the best comparison of the two sequences, the comparison window may include additions or deletions (i.e., spaces) of about 20% or less. The best comparison for comparing the sequences of the comparison window may be performed by computerized implementation of the algorithm (GAP, BESTFIT, FASTA, and TFASTA in Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, WI, USA) or by inspection and the best comparison (i.e., resulting in the highest percentage homology in the comparison window) produced by any method in the various methods selected. Reference may also be made to the BLAST program family, such as disclosed by Altschul et al., 1997, Nucl. Acids Res. 25: 3389. A detailed discussion of sequence analysis may be found in Ausubel et al., "Current Protocols in Molecular Biology", John Wiley & Sons Inc, 1994-1998, Section 15, Unit 19.3.

[0048] In one embodiment, the vector further comprises at least one spacer domain.The at least one spacer domain may be located between the 5' type 1 intron fragment and the IRES.

[0049] As used herein, "spacer" refers to a region of a polynucleotide sequence ranging from 1 nucleotide to hundreds or thousands of nucleotides, which separates two other elements along the polynucleotide sequence. The sequence may be limited or may be random. The spacer is typically non-coding. In some embodiments, the spacer includes a double formation region. "Spacer" may refer to any continuous nucleotide sequence, 1) predicted to avoid interfering with proximal structures, for example, from IRES, coding regions or non-coding regions, or introns, 2) at least 7 nucleotides long (and optionally not longer than 100 nucleotides), 3) downstream of 3' intron fragments and adjacent to 3' intron fragments and / or upstream of 5' intron fragments and adjacent to 5' intron fragments, and / or 4) containing one or more of the following: a) an unstructured region of at least 5nt long, b) to a region of predicted base pairing of at least 5nt long to a distal (i.e., non-adjacent) sequence, including another spacer, and / or c) a structured region of at least 7nt long of a sequence limited to a spacer.

[0050] In one embodiment, the spacer comprises a nucleic acid sequence having at least 70% sequence identity to SEQ ID NO:27 and / or SEQ ID NO:28.

[0051] As used herein, "interfering" with respect to a sequence refers to a sequence(s) that is predicted or empirically determined to alter the folding of other structures in the RNA, such as an IRES or group I intron-derived sequence.

[0052] As used herein, "unstructured" with respect to RNA refers to an RNA sequence that is not predicted by the RNAFold software or similar prediction tools to form a structure (e.g., a hairpin loop) with itself or other sequences in the same RNA molecule.

[0053] As used herein, "structured" with respect to RNA refers to an RNA sequence predicted by the RNAFold software or similar prediction tools to form a structure (e.g., a hairpin loop) with itself or other sequences in the same RNA molecule.

[0054] In some embodiments, the vector comprises an IRES sequence. The IRES sequence can be selected from, but is not limited to, the following IRES sequences: Taura syndrome virus, Triatoma virus, Theiler's encephalomyelitis virus, Simian virus 40, Solenopsisinvicta virus 1, Rhopalosiphum padi virus, Reticuloendotheliosis virus, fuman poliovirus 1, Plautia staliintestine virus, Kashmir bee virus, Human rhinovirus 2, Homalodisca coagulata virus-1, Human immunodeficiency virus type 1, Homalodisca coagulata virus-1, Himetobi P virus, hepatitis C virus, hepatitis A virus, hepatitis GB virus, foot-and-mouth disease virus, human enterovirus 71, equine rhinitis virus, Ectropis obliqua picorna-like virus, encephalomyocarditis virus (EMCV), fruit fly C virus, Crucifer tobamo virus, Cricket paralysisvirus, bovine viral diarrhea virus 1, Black Queen Cell Virus, Aphid lethal paralysis virus, Avian encephalomyelitis virus, Acute bee paralysis virus, Hibiscus chlorotic ringspot virus, Classical swine fever virusfevervirus), human FGF2, human SFTPA1, human AML1 / RUNX1, Drosophila antennapedia, human AQP4, human AT1R, human BAG-1, human BCL2, human BiP, human c-IAP1, human c-myc, human eIF4G, mouse NDST4L, human LEF1, mouse HIF1α, human n.myc, mouse Gtx, human p27kipl, human PDGF2 / c-sis, human p53, human Pim-1, mouse Rbm3, Drosophila reaper, canine Scamper, Drosophila Ubx, human UNR, mouse UtrA, human VEGF-A, human XIAP, Drosophila hairless, S.cerevisiae TFIID, S.cerevisiae YAP1, human c-src, human FGF-1, Simian picornavirus The wild-type IRES sequence can also be modified and is effective in the present invention. In some embodiments, the IRES sequence is about 50 nucleotides in length.

[0055] In one embodiment, the IRES is an IRES sequence from viral CVB3, human SAT1, human HK1, viral RhPV, human eIF4G1, viral HCV, viral HalIV, or circIRES9128.

[0056] In one embodiment, the IRES is an IRES sequence from the virus CVB3.The IRES may comprise or consist of a nucleic acid sequence having at least 70% sequence identity to SEQ ID NO:13.

[0057] A vector as defined herein may comprise protein coding regions or non-coding regions.

[0058] In one embodiment, the vector comprises a protein coding region. The protein coding region can encode a protein for therapeutic use or diagnostic use. In some embodiments, the protein can be any protein for therapeutic use or diagnostic use. For example, the protein coding region can encode a human protein or antibody. In some embodiments, the protein can be selected from, but not limited to, hFIX, SP-B, VEGF-A, human methylmalonyl-CoA mutase (hMUT), CFTR, cancer autoantigens, and other gene editing enzymes such as Cpf1, zinc finger nuclease (ZFN) and transcription activator-like effector nuclease (TALEN). In some embodiments, the protein can be a viral protein. The viral protein can be a SARS-CoV-2 spike protein or a dengue EV71 protein.

[0059] In one embodiment, the size of the protein coding region exceeds 1 kb.The protein coding region may encode a viral protein (such as a SARS-CoV-2 spike protein or a dengue EV71 protein).

[0060] In some embodiments, the protein is a chimeric antigen receptor (CAR) or T cell receptor (TCR) complex protein. The CAR or TCR complex protein may include an antigen binding domain specific for a tumor antigen.

[0061] In some embodiments, the protein coding region encodes an mRNA sequence. The mRNA can encode any polypeptide of interest, including any naturally or non-naturally occurring polypeptide or otherwise modified polypeptide. The polypeptide encoded by the mRNA can have any size and can have any secondary structure or activity. In some embodiments, the polypeptide encoded by the mRNA can have a therapeutic effect when expressed in a cell.

[0062] In another embodiment, the vector comprises a non-coding region. In some embodiments, the non-coding region may encode a sequence that changes cell behavior (such as, for example, lymphocyte behavior). In some embodiments, the non-coding sequence is antisense to the cell RNA sequence.

[0063] In some embodiments, the non-coding region encodes siRNA. siRNA may be able to selectively knock down or down-regulate the expression of a gene of interest. For example, siRNA can be selected to silence the gene associated with a specific disease, disease, or condition after administering a nanoparticle composition comprising siRNA to a subject in need. siRNA can include a sequence complementary to the mRNA sequence of a gene or protein of interest. In some embodiments, siRNA is an immunomodulatory siRNA.

[0064] In some embodiments, the non-coding region encodes shRNA. After the appropriate construct is delivered to the nucleus, the shRNA can be produced in the target cell. The constructs and mechanisms associated with shRNA are well known in the relevant art.

[0065] In one embodiment, the vector further comprises an RNA polymerase promoter. In another embodiment, the RNA polymerase promoter is a T7 viral RNA polymerase promoter, a T6 viral RNA polymerase promoter, an SP6 viral RNA polymerase promoter, a T3 viral RNA polymerase promoter, or a T4 viral RNA polymerase promoter.

[0066] In one embodiment, a precursor RNA is provided, comprising:

[0067] a) 5' group I intron fragment,

[0068] b) Internal ribosome entry site (IRES),

[0069] c) protein coding regions or non-coding regions, and

[0070] d) 3' group I intron fragment.

[0071] In one embodiment, the 5' type I intron fragment in the precursor RNA comprises or consists of a nucleic acid sequence having at least 70% sequence identity to the nucleic acid sequence encoded by any one of SEQ ID NO: 1, 3, 5, 7, 9 or 11.

[0072] In one embodiment, the 3' type I intron fragment in the precursor RNA comprises or consists of a nucleic acid sequence having at least 70% sequence identity to the nucleic acid sequence encoded by any one of SEQ ID NO: 2, 4, 6, 8, 10 or 12.

[0073] Disclosed herein is a method for producing circular RNA from a precursor RNA transcribed from a vector as defined herein, the method comprising: 2+ The precursor RNA is incubated in the presence of to generate circular RNA from the precursor RNA.

[0074] The buffer may be Hepes, Tris or other buffer. The temperature used may be about 55°C. In one embodiment, the method comprises mixing 25 mM NaCl, 15 mM MgCl 2 The precursor RNA was incubated at 55°C in the presence of 25 mM Hepes (pH 7.5).

[0075] The method may further comprise purifying the circular RNA.

[0076] Disclosed herein are circular RNAs produced by a vector as defined herein.

[0077] Disclosed herein is a method of expressing a protein in a cell, the method comprising transfecting a circular RNA as defined herein into the cell.

[0078] Disclosed herein is a vector for producing circular RNA, the vector comprising the following elements operably linked to each other and arranged in the following order: a) a 5' homologous sequence, b) an internal ribosome entry site (IRES), c) a protein coding region or a non-coding region, and d) a 3' homologous sequence.

[0079] As used herein, a "homologous domain" or "homologous sequence" is any continuous sequence that 1) is predicted to form base pairs with at least about 75% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, about 100%) of another sequence in RNA, such as another homology arm, 2) is at least 7 nt long and no longer than 250 nt, 3) is located before and adjacent to, or included in, a 3' intron fragment, and / or is located after and adjacent to, or included in, a 5' intron fragment, and optionally 4) is predicted to have less than 50% (e.g., less than 45%, less than 40%, less than 35%, less than 30%, less than 25%) base pairing with an unexpected sequence in RNA (e.g., a non-homologous arm sequence). A "strong homology arm" refers to a homology arm with a Tm greater than 50 degrees Celsius when base pairing with another homology arm in RNA.

[0080] Disclosed herein is a method of producing circular RNA from a precursor RNA transcribed from a vector as defined herein, the method comprising incubating the precursor RNA in the presence of a buffer and T4 RNA ligase I or II to produce circular RNA from the precursor RNA.

[0081] The buffer may be Hepes, Tris or other buffer. The temperature used may be about 55°C. In one embodiment, the method comprises mixing 25 mM NaCl, 15 mM MgCl 2 The precursor RNA was incubated at 55°C in the presence of 25 mM Hepes (pH 7.5).

[0082] Also provided herein is a circular RNA as defined herein for use as a medicament.

[0083] Also provided herein is a circular RNA as defined herein for use in treating a disease or condition in a subject.

[0084] As used herein, the term "treating" refers to partially or completely alleviating, relieving, ameliorating, inproving, relieving, delaying the onset of, inhibiting the progression of, reducing the severity of, and / or reducing the incidence of one or more symptoms or features of a particular infection, disease, disorder, and / or condition. For example, "treating" cancer can refer to inhibiting the survival, growth, and / or spread of a tumor. Treatment can be administered to subjects who do not show signs of a disease, disorder, and / or condition and / or to subjects who only show early signs of a disease, disorder, and / or condition for the purpose of reducing the risk of developing pathology associated with the disease, disorder, and / or condition.

[0085] The terms "subject", "patient", "host" or "individual" used interchangeably herein refer to any subject, particularly a vertebrate subject, and even more particularly a mammalian subject, in need of treatment or prevention. Suitable vertebrates falling within the scope of the present invention include, but are not limited to, any member of the subphylum Chordata including primates (e.g., humans, monkeys and apes, and including species such as monkeys from the genus Macaca (e.g., cynomolgus macaques such as Macaca fascicularis, and / or rhesus macaques (Macaca mulatta)) and baboons (Papio ursinus), as well as marmosets (species from the genus Callithrix), squirrel monkeys (species from the genus Saimiri) and tamarins (species from the genus Saguinus), and chimpanzees (Pan troglodytes) and chimpanzees. troglodytes), rodents (e.g., mice, rats, guinea pigs), lagomorphs (e.g., rabbits, hares), bovines (e.g., cattle), ovines (e.g., sheep), caprines (e.g., goats), porcines (e.g., pigs), equines (e.g., horses), canines (e.g., dogs), felines (e.g., cats), avian (e.g., chickens, turkeys, ducks, geese, companion birds such as canaries, budgies, etc.), marine mammals (e.g., dolphins, whales), reptiles (snakes, frogs, lizards, etc.), and fish. In one embodiment, the subject is a human subject.

[0086] The present specification also discloses nanoparticle compositions comprising the circular RNA as described herein.

[0087] As used herein, "nanoparticle compositions" are compositions comprising more than one lipid. Nanoparticle compositions are generally sized at micrometers or less and may include lipid bilayers. Nanoparticle compositions include lipid nanoparticles (LNPs), liposomes (e.g., lipid vesicles), and lipid complexes. For example, nanoparticle compositions may be liposomes having a lipid bilayer having a diameter of less than 500 nm.

[0088] As used herein, phrase " lipid nanoparticle " refers to the transfer vehicle (vehicle) comprising more than one lipid (for example, cationic lipid, non-cationic lipid and PEG modified lipid).Preferably, lipid nanoparticle is formulated as more than one mRNA is delivered to more than one target cell.The example of suitable lipid includes for example phosphatidyl compound (for example, phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipid, cerebroside and ganglioside).It is also expected to use polymer as transfer vehicle, no matter it is alone or in combination with other transfer vehicles.Suitable polymer can include for example polyacrylate, polyalkyl cyanoacrylate, polylactide, polylactide-polyglycolide copolymer, polycaprolactone, dextran, albumin, gelatin, alginate, collagen, chitosan, cyclodextrin, dendrimer and polyethyleneimine.

[0089] As used herein, "transfer vehicle" includes any standard pharmaceutical carriers, diluents, excipients, and the like, which are normally intended for use in conjunction with the administration of biologically active agents, including nucleic acids.

[0090] In some embodiments, the present invention also relates to compositions, for example, compositions comprising circular RNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions disclosed herein may comprise circular RNA as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, excipients or diluents. In some embodiments, the pharmaceutical compositions disclosed herein may comprise circular RNA expressing cells as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, excipients or diluents.

[0091] In some embodiments, a pharmaceutically acceptable carrier may be an ingredient in a pharmaceutical composition other than the active ingredient that is non-toxic to the subject.

[0092] Pharmaceutically acceptable carriers may include, but are not limited to, buffers, excipients, stabilizers, or preservatives. Examples of pharmaceutically acceptable carriers are physiologically compatible solvents, dispersion media, coatings, antibacterial and antifungal agents, and isotonic agents and absorption delay agents, etc., such as salts, buffers, sugars, antioxidants, aqueous or non-aqueous carriers, preservatives, wetting agents, surfactants or emulsifiers, or combinations thereof. The amount of pharmaceutically acceptable carriers (more than one) in the pharmaceutical composition can be determined experimentally based on the activity of the carrier (more than one) and the desired features of the preparation, such as stability and / or minimal oxidation.

[0093] In some embodiments, such compositions may include buffers such as acetic acid, citric acid, histidine, boric acid, formic acid, succinic acid, phosphoric acid, carbonic acid, malic acid, aspartic acid, Tris buffer, HEPPSO, HEPES, neutral buffered saline, and phosphate buffered saline, etc.; carbohydrates such as glucose, sucrose, mannose, or dextran, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); antibacterial and antifungal agents; and preservatives.

[0094] In certain embodiments, compositions of the present disclosure can be formulated for a variety of parenteral or non-parenteral administration modes. In one embodiment, compositions can be formulated for infusion or intravenous administration. Compositions disclosed herein can be provided as, for example, sterile liquid preparations, such as isotonic aqueous solutions, emulsions, suspensions, dispersants, or viscous compositions, which can be buffered to desired pH. Preparations suitable for oral administration can include liquid solutions, capsules, pouches, tablets, lozenges, and lozenges, suitable liquids, and powder liquid suspensions in emulsions.

[0095] In one embodiment, a method of preventing or treating a disease or condition in a subject is provided, the method comprising administering to the subject an effective amount of a vector, circular RNA, nanoparticle composition, or pharmaceutical composition as described herein.

[0096] In one embodiment, the disease or condition is a viral infection, such as a coronavirus (e.g., SARS-CoV-2) infection or a dengue infection. In another embodiment, the disease or condition is cancer.

[0097] The term "administering" refers to contacting, applying, injecting, infusing or providing a drug as mentioned herein to a subject.

[0098] In the case of treating or preventing a condition, "effective amount" means that an amount of an agent or composition is administered to an individual in need of such treatment or prevention, either in a single dose or as part of a series, which is effective in preventing the symptoms of the condition, keeping such symptoms in check, and / or treating existing symptoms. The effective amount will vary depending on the health and physical condition of the individual to be treated, the taxonomic group of the individual to be treated, the formulation of the composition, the assessment of the medical condition, and other relevant factors. It is expected that the amount will fall within a relatively wide range that can be determined by routine tests.

[0099] In some embodiments, circular RNA as described herein can be used in combination with other known agents and therapies. As used herein, "combination" administration means delivering two (or more) different treatments to a subject during the course of treatment of the subject, for example, after the subject has been diagnosed with a disease and before the disease has been cured or eliminated or treatment is stopped for other reasons. In some embodiments, when the delivery of the second treatment begins, the delivery of a treatment still occurs, so that there is overlap in terms of administration. This is sometimes referred to as "simultaneous" or "parallel delivery" in this article. In other embodiments, the delivery of a treatment ends before the delivery of another treatment begins. In some embodiments of either case, due to combined administration, treatment is more effective. For example, the second treatment is more effective, for example, compared to what will be seen when the second treatment is applied in the absence of the first treatment, an equivalent effect is seen in the case of less second treatment, or the second treatment reduces symptoms to a greater extent, or similar situations are seen in the case of the first treatment. In some embodiments, delivery makes the reduction of symptoms or other parameters related to the disease greater than the situation observed when a treatment is delivered in the absence of another treatment. The effect of the two treatments can be partial accumulation, full accumulation, or greater than accumulation. The delivery may be such that the effects of the first treatment delivered are still detectable when the second treatment is delivered.

[0100] In further embodiments, the compositions described herein can be used in combination with surgery, radiation, chemotherapy, antibodies, or other agents in a treatment regimen.

[0101] As used herein, "and / or" refers to and encompasses any and all possible combinations of more than one of the associated listed items, as well as the lack of a combination when interpreted in the alternative (or).

[0102] As used in this application, the singular forms "a", "an", and "the" include plural references unless the context clearly dictates otherwise. For example, the term "an agent" includes a plurality of agents, including mixtures thereof.

[0103] Throughout this specification and the statements that follow, unless the context requires otherwise, the words "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of stated integers or steps or groups of integers or steps but not the exclusion of any other integers or steps or groups of integers or steps.

[0104] Reference in this specification to any previous publication (or information derived therefrom), or to any matter known, is not and should not be taken as an acknowledgement or acknowledgment or any form of suggestion that the previous publication (or information derived therefrom) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

[0105] Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It should be understood that the invention includes all such variations and modifications that fall within the spirit and scope. The invention also includes all steps, features, compositions and compounds mentioned or indicated in this specification, either individually or collectively, and any and all combinations of any two or more of the steps or features.

[0106] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0107] Certain embodiments of the invention will now be described with reference to the following examples, which are intended for illustrative purposes only and are not intended to limit the general scope of the above description.

[0108] Example

[0109] Different conditions can be used to optimize circularization of RNA using T4 RNA ligase II.

[0110] Different homologous sequences (such as from AnCS20 and Dengue (DVCS26)) were tested to bring the 5' and 3' ends of the RNA close to each other, different treatment conditions to enable the ends to be ligation compatible, and different ligases and times to identify the conditions that promote the most efficient circularization. For 1 kb long RNA, it was found that the use of T4 RNA ligase 2 and overnight ligation produced ∼53% circularized RNA ( Figure 3 ).

[0111] Design of self-circularizing RNAs that replace group 1 introns using RNA from naturally occurring ribozymes.

[0112] Group 1 introns are a class of autocatalytic RNAs that can splice their own introns and are found in diverse organisms including T4 bacteriophage (T4) and Anabaena (An). All group I introns share a conserved structure that builds the core ribozyme region ( Figure 4 ), the conserved secondary structure of type 1 introns includes 9 paired regions numbered P1-P9, and the splice sites (5'-ss and 3'-ss) are indicated by arrows. All type I introns contain these paired regions, except P2. Replacement type I introns can be generated by cutting at P6 without affecting the 5' and 3' splicing activities. Attaching the replacement end of the type I intron to the terminal end of the linear RNA enables reverse splicing, which leads to autocatalytic cyclization.

[0113] A split intron-exon strategy was used to identify novel type 1 introns that could be used to generate circular RNAs.

[0114] Several member type 1 introns, such as those from T4 phage and from Anabaena, have been used to produce circular RNA with high efficiency by self-splicing. However, most type 1 introns only match well with short inserts of several hundred bases. Since many genes of interest are long (e.g., spike protein is 4 kb, and VP1-3 protein from EV71 is 2.5 kb), the self-splicing efficiency of type 1 introns from different organisms is tested using inserts of different lengths. Except for T4 and An, whose type 1 introns are known to be able to use the broken intron-exon strategy to make RNA cyclization, 6 different type I introns (Sd, Clostridium botulinum (Cb), Sh, Green White Joe Smith mold (Gv), Penicillium oblate (Po) and Xylaria officinalis (Bo)) are designed and tested for their self-splicing and therefore the ability to make RNA cyclization in the presence of Gluc as an insert ( Figure 5 ). Seven different folding conditions (AG) for the self-splicing efficiency of different type 1 introns were also tested, since each intron may require different folding conditions for self-splicing.

[0115] Since RNA self-splicing can sometimes introduce errors such as insertions and deletions between splice sites, the accuracy of self-splicing of these type 1 introns was checked by reverse transcription, PCR followed by Sanger sequencing on circular RNA. Self-splicing junctions were classified into three categories: 1) completely accurate, 2) some insertions and deletions that do not affect the gene of interest, and 3) errors that destroy the gene of interest and therefore will not be expressed correctly. Sd was observed to contain the largest number of highly accurate junctions, followed by Po, An, and T4 ( Figure 6 ), suggesting that they could be good candidates for RNA circularization.

[0116] Newly designed group 1 introns and T4 RNA ligase 2 can outperform existing group 1 introns in protein production ( Figure 7 ).

[0117] Identification of an IRES for high circular RNA translation

[0118] Unlike the cap-dependent translation mechanism in mRNA, endless circular RNA uses IRES (internal ribosome entry sequence) for cap-independent protein translation. A panel of IRES from different viral and human sources was tested to identify an IRES that can drive strong translation ( Figure 8 The best candidate can be tested for translation efficiency in different cellular environments using different GOIs (genes of interest).

[0119] Strategies for circular RNA purification, amplification, and QC.

[0120] As part of the nucleic acid manufacturing process, it is necessary to develop efficient downstream bioprocesses for enriching pure circular RNAs. Therefore, a general production pipeline was developed specifically for circular RNAs ( Fig. 9 a). Briefly, linear RNA containing a replacement group I intron was transcribed in vitro from a linearized DNA template and then expressed using Figure 3 The linear / circular RNA mixture was then treated with a specific concentration of RNase R to remove most of the linear RNA ( Fig. 9 b).

[0121] The workflow for producing circular RNA follows standard mRNA manufacturing practices and is manufactured in an RNA factory to produce GMP-grade RNA and nanoparticles for vaccine production and clinical trials. The steps for making circular RNA are outlined in detail ( Fig.10 ). Briefly, a DNA plasmid containing a replacement group I intron, an IRES, and a gene of interest is amplified using bacterial culture, the plasmid is purified and linearized using restriction enzyme digestion, followed by in vitro transcription using RNA polymerase, followed by circularization of the linear RNA under specific folding conditions. Finally, Fig. 9 The circular RNA will be purified using the chromatography technique described in . QC will be performed on the circular RNA by reverse transcription, library preparation and deep sequencing. Only circular RNA with a high proportion of accurate junctions will be used in downstream packaging.

[0122]

[0123]

[0124]

[0125]

[0126]

[0127]

[0128]

[0129]

[0130]

[0131]

[0132]

[0133]

[0134]

[0135]

[0136]

Claims

1. A vector for producing circular RNA, the vector comprising the following elements operably linked to each other and arranged in the following order: a) 5' group I intron fragment, b) Internal ribosome entry site (IRES), c) protein coding regions or non-coding regions, and d) 3' group I intron fragment.

2. The vector of claim 1, wherein the vector further comprises at least one spacer domain.

3. The vector according to claim 1 or 2, wherein the 5' and 3' type I intron fragments are from Scytalidium dimidiatum (Sd), Clostridium botulinum (Cb), Scytonema hofmanii (Sh), Geosmithia virida (Gv), Penicillium oblatum (Po) or Barrmaelia oxyacanthae (Bo).

4. The vector according to any one of claims 1 to 3, wherein the 5' type I intron fragment comprises or consists of a nucleic acid sequence having at least 70% sequence identity with SEQ ID NO:5, and the 3' type I intron fragment comprises or consists of a nucleic acid sequence having at least 70% sequence identity with SEQ ID NO:

6.

5. The vector according to claim 1 or 2, wherein the 5' type I intron fragment comprises or consists of a nucleic acid sequence having at least 70% sequence identity with SEQ ID NO: 25, and the 3' type I intron fragment comprises or consists of a nucleic acid sequence having at least 70% sequence identity with SEQ ID NO:

26.

6. The vector according to any one of claims 1 to 5, wherein the IRES is an IRES sequence from virus CVB3, human SAT1, human HK1, virus RhPV, human eIF4G1, virus HCV, virus HalIV or circIRES9128.

7. The vector according to any one of claims 1 to 6, wherein the size of the protein coding region exceeds 1 kb.

8. The vector according to any one of claims 1 to 7, wherein the protein coding region encodes mRNA.

9. The vector according to any one of claims 1 to 8, wherein the protein coding region encodes a viral protein. 10 . The vector according to claim 1 , wherein the vector further comprises an RNA polymerase located upstream of the 5′ type I intron fragment.

11. The vector according to claim 10, wherein the RNA polymerase promoter is an RNA polymerase promoter from T7 virus, T6 virus, SP6 virus, T3 virus, or T4 virus.

12. A method for producing circular RNA from a precursor RNA transcribed from a vector according to any one of claims 1 to 11, the method comprising: 2+ The precursor RNA is incubated in the presence of to generate circular RNA from the precursor RNA.

13. The method of claim 12, wherein the method further comprises purifying the circular RNA.

14. A circular RNA produced by the vector according to any one of claims 1 to 11.

15. A method for expressing a protein in a cell, the method comprising transfecting the circular RNA according to claim 14 into the cell.

16. A nanoparticle composition comprising a circular RNA produced by the vector according to any one of claims 1 to 11.

17. A vector for producing circular RNA, the vector comprising the following elements operably linked to each other and arranged in the following order: a) 5' homologous sequence, b) Internal ribosome entry site (IRES), c) protein coding regions or non-coding regions, and d) 3' homologous sequence.

18. A method for producing circular RNA from a precursor RNA transcribed from a vector according to claim 17, the method comprising: 2+ and T4 RNA ligase I or II to generate circular RNA from the precursor RNA.